liking schizophrenia

Augmentation Strategies for Depression | Psychiatric Times

Reading now: 374

Several years ago, I was approached by a pharmaceutical representative who wanted to tell me about a “new” agent, brexpiprazole.

Sure, I was familiar with it having learned about it in training—the serotonin 1A and dopamine D2 receptors partial agonist and serotonin 2A and noradrenaline alpha receptors antagonist that was FDA-approved for schizophrenia and as adjunctive therapy to antidepressant for major depressive disorder (MDD).1 But there is no way I would use it; after all it was likely just another “pharma” push of a drug that would not work, right?At least in academia we have been groomed to see such advancements as an advertisement or a marketing scheme, and it is taboo to engage in discussions, let alone prescribe, a marketed drug.

The website is an aggregator of articles from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the article if you find it unreliable.

Related articles